Hematopoietic cells are often obtained from bone marrow, peripheral blood and umbilical cord blood, albeit in very limited numbers. The ability to expand hematopoietic progenitor populations can be difficult to achieve. A successful expansion must provide sufficient numbers of fully functional hematopoietic progenitor cells that are able to self-renew and differentiate into all functional blood cells.
Manufactured under cGMP conditions
Optimized to support vigorous expansion of hematopoietic progenitor cells while maintaining functionality
Manufactured to be scalable and facilitate transfer from research to clinic
Drug Master File (DMF) registration
Custom packaging and modifications available
Figure 1 CD34+ hematopoietic progenitor cells derived from human cord blood were cultured in PRIME-XV Hematopoietic Cell Basal XSFM or a commercially-available xeno-free expansion medium, both supplemented with a cocktail of cytokines (TPO, SCF, FLT-3L, IL-3 and IL-6). After 3, 7 and 9 days, the TNC (A) and fold expansion (B) of CD34+ cells were quantified.
This product is shipped at 2-8°C. Upon receipt, store immediately at 2-8°C and protect from light.
Handle using aseptic techniques to avoid contamination. Unopened liquid medium is stable for 12 months from date of manufacture, as indicated on the label.